Balaña, C. http://orcid.org/0000-0003-0771-0390
Estival, A.
Teruel, I.
Hardy-Werbin, M.
Sepulveda, J.
Pineda, E.
Martinez-García, M.
Gallego, O.
Luque, R.
Gil-Gil, M.
Mesia, C.
Del Barco, S.
Herrero, A.
Berrocal, A.
Perez-Segura, P.
De las Penas, R.
Marruecos, J.
Fuentes, R.
Reynes, G.
Velarde, J. M.
Cardona, A.
Verger, E.
Panciroli, C.
Villà, S.
Funding for this research was provided by:
Fundació la Marató de TV3 (665/C/2013)
Instituto de Salud Carlos III (EC08/00071)
Article History
Received: 5 February 2018
Accepted: 23 April 2018
First Online: 8 May 2018
Compliance with ethical standards
:
: Carmen Balaña declares an advisory position for AbbVie and Amgen and financial support for attending symposia of Pharmamar. The remaining authors declare that they have no conflict of interest.
: The studies were approved by the Ethics Committee of each participating hospital.
: Written informed consent was obtained from all patients before registration in trials/projects of the GEINO and GLIOCAT groups.